US 11,891,379 B2
Deuterated Defactinib compound and use thereof
Wu Du, Sichuan (CN); Yu Li, Sichuan (CN); Kun Wen, Sichuan (CN); Xinghai Li, Sichuan (CN); and Yuanwei Chen, Sichuan (CN)
Assigned to HINOVA PHARMACEUTICALS INC., Sichuan (CN)
Appl. No. 17/054,080
Filed by HINOVA PHARMACEUTICALS INC., Sichuan (CN)
PCT Filed May 6, 2019, PCT No. PCT/CN2019/085722
§ 371(c)(1), (2) Date Nov. 9, 2020,
PCT Pub. No. WO2019/214587, PCT Pub. Date Nov. 14, 2019.
Claims priority of application No. 201810427571.1 (CN), filed on May 7, 2018.
Prior Publication US 2021/0238166 A1, Aug. 5, 2021
Int. Cl. A61K 31/506 (2006.01); C07D 403/12 (2006.01)
CPC C07D 403/12 (2013.01) [C07B 2200/05 (2013.01)] 12 Claims
 
1. A compound of formula (I) or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof:

OG Complex Work Unit Chemistry
wherein, R1-R18 are each independently selected from hydrogen and deuterium, with the proviso that not all of them are hydrogen at the same time.